Seed · Healthtech · London, United Kingdom · Founded 2019 · 30–50 employees
Digistain has developed a breakthrough AI-powered diagnostic technology for breast cancer that delivers risk assessment results in just 15 minutes, compared to weeks or months with traditional methods. The technology uses infrared spectroscopy to analyze tissue samples without requiring chemical staining, helping doctors identify which patients can safely avoid chemotherapy. The company has received regulatory approval from the UK's MHRA and has validated its technology in clinical trials involving over 800 patients, showing it can identify 49% of low-risk patients who may forgo adjuvant chemotherapy. Digistain has raised $1 million in seed funding from Y Combinator, Sofia Angels Ventures, and other investors, and has been recognized with awards from the Royal Society, Cancer Research UK, and the Institute of Physics.
No open roles listed right now.